Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Piper Sandler Reaffirms Their Buy Rating on Regeneron (REGN)

Tipranks - Tipranks - Sat Apr 11, 6:18AM CDT

Piper Sandler analyst Biren Amin maintained a Buy rating on Regeneron today and set a price target of $875.00.

Easter Sale - 70% Off TipRanks

Amin covers the Healthcare sector, focusing on stocks such as Ocular Therapeutix, Sarepta Therapeutics, and Crescent Biopharma. According to TipRanks, Amin has an average return of 7.8% and a 45.88% success rate on recommended stocks.

In addition to Piper Sandler, Regeneron also received a Buy from Bernstein’s William Pickering in a report issued on April 8. However, yesterday, Wells Fargo maintained a Hold rating on Regeneron (NASDAQ: REGN).

See Insiders’ Hot Stocks on TipRanks >>

Based on Regeneron’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $3.88 billion and a net profit of $844.6 million. In comparison, last year the company earned a revenue of $3.79 billion and had a net profit of $917.7 million

Read More on REGN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).